中关村：丹麦药品管理局、AMGROS到访，共商产业未来发展新机遇

Group 1 - The visit by Danish officials aims to deepen mutual understanding in the pharmaceutical sector between Denmark and China, exploring new cooperation opportunities in innovative drug development, digital healthcare, and sustainable development [1] - The Danish side shared experiences in international cooperation, drug cost management, and regulatory frameworks, while the company showcased its production capabilities and multi-product pipeline in various therapeutic areas [1] - Discussions focused on international trends in drug evaluation and approval, patient-centered drug development, and the application of new tools and methods in regulatory decision-making [1] Group 2 - AMGROS, representing Denmark's public healthcare system, aims to ensure the accessibility of innovative drugs while achieving nearly 50% savings in drug procurement costs through competitive bidding and innovative agreements [2] - The exchange with Danish officials is seen as a strategic alignment that provides valuable opportunities for the company to integrate into the global pharmaceutical innovation network and align with international standards [2] - The company is enhancing its market competitiveness in cardiovascular products and expanding its product matrix in narcotic drugs, while actively promoting pharmaceutical innovation to seek new growth avenues [2]